Compare PXED & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | PCRX |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | PXED | PCRX |
|---|---|---|
| Price | $29.61 | $23.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $44.29 | $30.25 |
| AVG Volume (30 Days) | 81.6K | ★ 513.2K |
| Earning Date | 04-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $3.85 | $6.78 |
| Revenue Next Year | $4.49 | $8.54 |
| P/E Ratio | ★ $11.20 | $330.36 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $23.52 | $18.80 |
| 52 Week High | $38.19 | $27.64 |
| Indicator | PXED | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 47.26 |
| Support Level | $28.60 | $20.15 |
| Resistance Level | $30.68 | $24.20 |
| Average True Range (ATR) | 1.35 | 1.28 |
| MACD | 0.12 | -0.25 |
| Stochastic Oscillator | 57.27 | 25.08 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.